Meeting
2012 ASCO Annual Meeting
Phase II study of everolimus (E) in refractory germ cell tumors (GCTs).
Authors
Michal Mego
Department of Medical Oncology, School of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia
Michal Mego , Daniela Svetlovska , Jana Obertova , Maria Reckova , Viera Miskovska , Jan Rajec , Zuzana Sycova-Mila , Patrik Palacka , Stefania Liskova , Michal Chovanec , Tomas Salek , Jozef Mardiak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
NCT01466231
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS4677)
DOI
10.1200/jco.2012.30.15_suppl.tps4677
Abstract #
TPS4677
Poster Bd #
14D
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC).
First Author: Bradley Alexander McGregor
Poster
2012 ASCO Annual Meeting
Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09).
First Author: Guenter Niegisch
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2023 ASCO Genitourinary Cancers Symposium
Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
First Author: Adrish Sen